Published February 2018 | Version v1
Journal article

Neurotoxic effect of oxaliplatin: Comparison with its oxalate-free analogue cis-[PtII(1R,2R-DACH)(3-acetoxy-1,1-cyclobutanedicarboxylato)] (LLC-1402) in mice

  • 1. Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, 60430-270 Fortaleza, CE (Brazil)
  • 2. Department of Morphology, Faculty of Medicine, Federal University of Ceará, 60430-170 Fortaleza, CE (Brazil)
  • 3. Department of Clinical Medicine, Faculty of Medicine, Federal University of Ceará, 60430-140, Fortaleza, CE (Brazil)

Description

Highlights: • Oxaliplatin oxalate-free analogue induced peripheral sensory neuropathy. • Oxaliplatin oxalate-free analogue seems to lead to neuronal damage. • Oxalate may contribute to oxaliplatin-induced peripheral sensory neuropathy. • Oxalate seems to induce increased neuronal activity, but not neuronal damage. Studies suggest that oxalate is involved in the development oxaliplatin-induced peripheral sensory neuropathy (OPSN). This study aimed to compare the neurotoxic effects of oxaliplatin with its oxalate-free cytotoxic analogue cis-[PtII(1R,2R-DACH)(3-acetoxy-1,1-cyclobutanedicarboxylato)] (LLC-1402) in mice. Oxaliplatin and LLC-1402 were intravenously injected in male Swiss mice with a total of nine injections. Oxalate was intraperitoneally injected in other animals. The development of OPSN was evaluated using mechanical and thermal sensitivity tests. Dorsal root ganglia of the mice were removed to evaluate c-Fos, ATF3 and iNOS expression and a sample of blood was collected for leukocyte count and hepatic and renal biochemical function tests. Oxaliplatin and LLC-1402 decreased the mechanical and thermal nociceptive threshold, whilst oxalate lead to a partial and later increase in the mechanical sensitivity (P < 0.05). c-Fos, ATF3 and iNOS expressions were increased in neuronal cells during and after the end of the injections in animals treated with oxaliplatin and LLC-1402 (P < 0.05), even though oxaliplatin lead to an earlier increase. Only c-Fos expression was elevated during the period of injections in the oxalate group (P < 0.05), but this expression reduced after the end of the treatment. c-Fos expression was also shown in glial satellite cells only in the oxaliplatin-treated animals. Oxaliplatin and LLC-1402 reduced leukocyte count (P < 0.05), but did not change renal and liver functions. In conclusion, oxalate may contribute to an earlier development of peripheral sensory neuropathy. However, the antitumor cytotoxic mechanism of oxaliplatin seems to be the main responsible by its neurotoxic effect.

Availability note (English)

Available from http://dx.doi.org/10.1016/j.taap.2018.01.001

Additional details

Identifiers

DOI
10.1016/j.taap.2018.01.001;
PII
S0041008X18300012;

Publishing Information

Journal Title
Toxicology and Applied Pharmacology
Journal Volume
340
Journal Page Range
p. 77-84
ISSN
0041-008X
CODEN
TXAPA9

INIS

Country of Publication
United States
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
54106776
Subject category
S60: APPLIED LIFE SCIENCES;
Descriptors DEI
KIDNEYS; LEUKOCYTES; LIVER; MICE; OXALATES
Descriptors DEC
ANIMALS; BIOLOGICAL MATERIALS; BLOOD; BLOOD CELLS; BODY; BODY FLUIDS; CARBOXYLIC ACID SALTS; DIGESTIVE SYSTEM; GLANDS; MAMMALS; MATERIALS; ORGANS; RODENTS; VERTEBRATES

Optional Information

Copyright
Copyright (c) 2018 Elsevier Inc. All rights reserved.